Printer Friendly

SMITHKLINE BEECHAM ACQUIRES VACCINE COMPANY IN GERMANY

 SMITHKLINE BEECHAM ACQUIRES VACCINE COMPANY IN GERMANY
 PHILADELPHIA, April 28 /PRNewswire/ -- SmithKline Beecham (NYSE: SBH) (SB) announced today the signing of an agreement to acquire Sachsisches Serumwerk GmbH (SSW), a former East German vaccine manufacturer, for an undisclosed sum.
 This contract is between SB and the Treuhandanstaldt, the existing owners who are handling the privatization of some 10,000 existing businesses in the former GDR.
 Sachsisches Serumwerk GmbH is based in Dresden, Germany, and was until the unification of Germany the sole producer of human vaccines in the GDR. SSW has benefited from substantial capital investment and has a modern plant. It has the current capacity to produce several million doses of flu vaccine annually, with significant potential to expand. The company also has a highly qualified technical staff.
 "This acquisition marks an important step in the strategic development of our human vaccine policy," said Jan Leschly, chairman of Worldwide Pharmaceuticals at SB. "SmithKline Beecham Biologicals is one of a few major worldwide vaccine producers which has no existing flu manufacturing facilities. This investment in SSW therefore represents excellent commercial logic and is an important addition to our portfolio of vaccine products in Europe."
 SmithKline Beecham -- one of the world's leading healthcare companies -- discovers, develops, manufactures and markets human and animal pharmaceuticals, biologicals, over-the-counter medicines, health- related consumer brands and clinical laboratory testing services. SB markets its more than 300 products in over 130 countries.
 /delval/
 -0- 4/28/92
 /CONTACT: Jeremy Heymsfeld (media), 215-751-5166, or Richard Williams (investor relations), 215-751-7002, both of SmithKline Beecham/
 (SBH) CO: SmithKline Beecham; Sachsisches Serumwerk GmbH ST: Pennsylvania IN: MTC SU: TNM


KA-JS -- PH003 -- 3522 04/28/92 07:40 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 28, 1992
Words:277
Previous Article:TROPICANA LAUNCHES NEW PROGRAM OFFERING FREE NIGHT TO PLAYERS
Next Article:MAGMA COPPER REPORTS NET INCOME OF $9.7 MILLION OR $0.22 PER SHARE FOR FIRST QUARTER 1992


Related Articles
MICHIGAN DEPARTMENT OF PUBLIC HEALTH AND SMITHKLINE BEECHAM ANNOUNCE VACCINE COLLABORATION
PASTEUR MERIEUX SERUMS ET VACCINS AND SMITHKLINE BEECHAM ANNOUNCE VACCINE AGREEMENT
SMITHKLINE BEECHAM AND YALE UNIVERSITY ANNOUNCE AGREEMENT ON LYME DISEASE VACCINE
CAMBRIDGE BIOTECH CORPORATION AND SMITHKLINE BEECHAM SIGN VACCINE ALLIANCE
CAMBRIDGE BIOTECH CORPORATION AND SMITHKLINE BEECHAM SIGN VACCINE ALLIANCE
SMITHKLINE BEECHAM AND YALE UNIVERSITY ANNOUNCE AGREEMENT ON LYME DISEASE VETERINARY VACCINE
NEW DIPHTHERIA, TETANUS AND ACELLULAR PERTUSSIS VACCINE EFFECTIVE FOR PRIMARY VACCINATION FOR CHILDREN, STUDY SHOWS
SMITHKLINE BEECHAM ANNOUNCES PEDIATRIC VACCINE AGREEMENT WITH MEDEVA
GERMANY IS FIRST WORLDWIDE LAUNCH FOR SMITHKLINE BEECHAM'S NEW ACELLULAR PERTUSSIS VACCINE, INFANRIX
SMITHKLINE BEECHAM'S INFANRIX VACCINE APPROVED IN SWEDEN; SMITHKLINE BEECHAM ANNOUNCES DISTRIBUTION AGREEMENT WITH SBL VACCIN AB

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters